Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

Related Keywords

China ,Shanghai ,Hangzhou ,Zhejiang ,Suzhou ,Jiangsu ,Princeton ,Massachusetts ,United States ,Beijing ,Guangzhou ,Guangdong ,Madrid ,Spain ,Boston ,Caroline Germa ,Los Angeles ,Transcenta Holding ,Transcenta Immune Tolerance Breaking Technology ,Transcenta Holding Limited ,Clinical Development Centers In Princeton ,Translational Research Center ,Product Development Center ,Global Medicine Development ,Group Headquarters ,Executive Vice President ,Chief Medical ,Manageable Safety ,Immune Tolerance Breaking Technology ,Orphan Drug Designation ,Manufacturing Facility ,Clinical Development Centers ,External Partnering Center ,Suzhou Industrial ,